Search
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L32868] Sugemalimab was under investigation in the clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma). … [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology.
Tenofovir
go.drugbank.com/drugs/DB14126Investigational[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order … [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Moclobemide
go.drugbank.com/drugs/DB01171ApprovedInvestigationalMost meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (
Synonyms: 4-Chlor-N-(2-morpholinoethyl)benzamid, p-Chloro-N-(2-morpholinoethyl)benzamideFerumoxides
go.drugbank.com/drugs/DB09508ApprovedCategories: Compounds used in a research, industrial, or household settingImidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnIt has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612] … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
GI-4000
go.drugbank.com/drugs/DB05698InvestigationalA vaccine containing a heat-killed recombinant <em>Saccharomyces cerevisiae</em> yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant
p-tert-Butylphenol-formaldehyde resin (low molecular weight)
go.drugbank.com/drugs/DB14190Approvedp-tert-Butylphenol-formaldehyde resin is a widely used adhesive chemical used in a wide variety of commercially available products and a known dermatological sensitizer and allergen [A34290,A34291].